Liraglutide
Also known as Victoza, Saxenda
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing. 97% homology to native GLP-1.
Regulatory Pathway
Dosing Protocol
Typical Dose
1.8-3 mg daily
Frequency
Once daily
Duration
Long-term / chronic use
Timing & Administration
Administer via Subcutaneous injection daily. Frequency: Once daily.
Popular Uses
Mechanism of Action
Extended half-life GLP-1 analog that slows gastric emptying, increases insulin secretion, suppresses glucagon, and affects brain appetite centers to reduce hunger.
Research Summary
Evidence level: fda approved. Clinical status: FDA Approved for diabetes (Victoza) and weight loss (Saxenda).
Side Effects & Safety
Important Warnings
- Boxed warning for thyroid C-cell tumors
References
No references available.
Related Peptides
Browse all →A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
View profileA dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.
View profileA triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.
View profile